voclosporin
Focal Segmental Glomerulosclerosis (FSGS)
Key Facts
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to delivering new treatment options to patients with autoimmune diseases. Its primary achievement is the FDA approval and commercialization of LUPKYNIS (voclosporin), a novel calcineurin inhibitor for lupus nephritis, a serious kidney manifestation of systemic lupus erythematosus. The company is strategically focused on maximizing the commercial potential of LUPKYNIS while exploring its application in other autoimmune indications. Aurinia's mission centers on addressing significant unmet medical needs in nephrology and rheumatology.
View full company profileAbout Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to delivering new treatment options to patients with autoimmune diseases. Its primary achievement is the FDA approval and commercialization of LUPKYNIS (voclosporin), a novel calcineurin inhibitor for lupus nephritis, a serious kidney manifestation of systemic lupus erythematosus. The company is strategically focused on maximizing the commercial potential of LUPKYNIS while exploring its application in other autoimmune indications. Aurinia's mission centers on addressing significant unmet medical needs in nephrology and rheumatology.
View full company profileTherapeutic Areas
Other Focal Segmental Glomerulosclerosis (FSGS) Drugs
| Drug | Company | Phase |
|---|---|---|
| Sparsentan | Travere Therapeutics | Phase 3 |